mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Abroad (travel likely)RecruitingPHASE3
Conditions
Colorectal Cancer (CRC) · pMMR/MSS Adenocarcinoma of the Colon or Rectum
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Study leads
Jun Huang, MD
Principal Investigator
The Sixth Affiliated Hospital, Sun Yat-sen University